<DOC>
	<DOC>NCT02384941</DOC>
	<brief_summary>This Phase 3 study is intended to demonstrate superiority of either Sotagliflozin High dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult patients with type 1 diabetes mellitus (T1D) who have inadequate glycemic control with insulin therapy.</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Patient has given written informed consent to participate in the study in accordance with local regulations Adult patients 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent Patients are being treated with insulin or insulin analog delivered via CSII or MDI Willing and able to perform SMBG and complete the study diary as required per protocol At the Screening Visit, A1C must be between 7.0% to 11.0% Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test Use of antidiabetic agent other than insulin or insulin analog at the time of screening Use of sodiumglucose cotransporter (SGLT) inhibitors within 8 weeks prior to randomization Chronic systemic corticosteroid use Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>